After the success of the 10th anniversary of the World Stem Cells & Regenerative Medicine Congress in 2015, it is time once again for the stem cells and regenerative medicine industries to come together and this time look forward to the next 10 years of commercial successes within these two sectors.
The Congress has traditionally focussed on developing the commercial aspects of stem cells, with the addition of innovation within regenerative medicine, notably tissue engineering.
Now the first cell therapies have made it to market, it is important, for the success of the sector, to move forward and include new projects and innovations that are coming out of academia and university spin-outs. These will be both new developments in cell therapy but also within the use of stem cells for drug discovery.
Alongside the stem cells content, there is an increasing amount of demand for other forms of regenerative medicine and so the Congress will move to include more commercial opportunities within the field of tissue engineering: markedly biological scaffolds, 3D bioprinting and organ regeneration.
Through the last 10 years the Congress has built up a reputation for delivering high-level commercial content and bringing together the senior executives and thought-leaders within the space. As the Congress moves to look forward to the next 10 years, the Congress will incorporate insights and attendance from across the value chain: from innovation through to application.
The Congress has traditionally focussed on developing the commercial aspects of stem cells, with the addition of innovation within regenerative medicine, notably tissue engineering.
Now the first cell therapies have made it to market, it is important, for the success of the sector, to move forward and include new projects and innovations that are coming out of academia and university spin-outs. These will be both new developments in cell therapy but also within the use of stem cells for drug discovery.
Alongside the stem cells content, there is an increasing amount of demand for other forms of regenerative medicine and so the Congress will move to include more commercial opportunities within the field of tissue engineering: markedly biological scaffolds, 3D bioprinting and organ regeneration.
Through the last 10 years the Congress has built up a reputation for delivering high-level commercial content and bringing together the senior executives and thought-leaders within the space. As the Congress moves to look forward to the next 10 years, the Congress will incorporate insights and attendance from across the value chain: from innovation through to application.
